Aptevo Therapeutics Inc.
APVO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001671584
No open-market purchases or sales by Aptevo Therapeutics Inc. insiders were filed in the last 90 days; 9 institutions reported holding it in 13F filings for Q2 2026, worth $224.3K in total; no superinvestor holds it.
Q4 2023 vs. Q3 2023
How the institutions holding Aptevo Therapeutics Inc. changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Q4 2023 | Change |
|---|---|---|---|
| Holders | 26 | 29 | +3 |
| Shares | 3.41M | 1.93M | −1.48M (−43.3%) |
| Value | $1.13M | $349.7K | −$776.0K (−68.9%) |
New holders (5)
Institutions that held Aptevo Therapeutics Inc. at the end of Q4 2023 but not at the end of Q3 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Citadel Advisors LLC | 262,124 | $47.4K | 0.00% |
| Squarepoint Ops LLC | 138,697 | $25.1K | 0.00% |
| Millennium Management LLC | 104,608 | $18.9K | 0.00% |
| Two Sigma Securities, LLC | 11,248 | $2.04K | 0.00% |
| Baader Bank INC | 15,086 | $2.03K | 0.00% |
Sold out (2)
Institutions that held Aptevo Therapeutics Inc. at the end of Q3 2023 and filed for Q4 2023 without it.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Price T Rowe Associates Inc | 46,200 | $16.0K |
| Earnest Partners LLC | 14 | $5 |